The synthesis and the characterization of nanoscale biomaterials, the innovative applications of “smart nanoparticles”, and the technological/biological impact of nanoscale systems are just some of the areas of focus in the field known as nanobiotechnology. Nanobiotechnology has a wide array of applications: from organ-on-a-chip technologies to nano-biosensors and nanocatalysts, from nanodiagnostics to advanced characterisation and imaging tools, from intelligent drug delivery to artificial bioconstructs, and from functional nanostructured surfaces to smart materials and nanofluidics. In all of these applications, it is important to consider the nanotoxicological and possible harmful impact of nanomaterials on living organisms. In fact, the evaluation of the safety of an innovative nanodevice is a process that should start at the very first step of concept and design. Particular attention should also be paid to the translational and regulatory aspects of nanobiomedical devices, in order to realize their practical application in future clinical practice.
In this thematic issue, we invite contributions on novel concepts, ingenious designs and promising applications related to nanobiotechnology. The submitted works are expected to feature, but are not limited to, the following topics:
Download all of the current publications in this thematic issue by clicking on "Download Issue".
Figure 1: Number of publications over the last five years on the synthesis of nanoparticles (NPs)/nanomateria...
Figure 2: Cytotoxicity of anisotropic gold metal nanoparticles in vitro and in vivo.
Figure 3: Synthesis of gold nanoparticles of different shapes using the seed-mediated approach. Chitosan was ...
Figure 4: A deep eutectic solvent as green solvent in the synthesis of anisotropic nanoparticles (flower shap...
Figure 5: Carrageenan as capping and reducing agent for gold nanoparticle synthesis. (A) Histogram for the si...
Figure 6: (A) A κ-carrageenan-stabilized hydroxyapatite rod-shaped nanocomposite. (B) Antibacterial study usi...
Figure 1: SARS-CoV-2 bound to the ACE2 receptor. (a) Crystallized complex between the RBD of the SARS-CoV-2 s...
Figure 2: Peptide candidates (blue) docked to the SARS-CoV-2 RBD (white). (a) ACE2 control peptide (red), (b)...
Figure 3: Superimposition of docked ACE2 (blue) onto the crystallized complex (red) in the active site using ...
Figure 4: Mapping of the number of hydrogen bonds formed between APD and lysozyme peptide candidates to the S...
Figure 5: Plots of the peptide secondary structure and charge as functions of the binding energy. (a) Relatio...
Figure 6: Crystallized ACE2 peptide (I21 to S44) bound to the SARS-CoV-2 RBD.
Figure 7: Binding affinity calculated using the PRODIGY server from ADV results. The binding affinities were ...
Figure 1: Photographs of Ag/AgCl nanoparticle biosynthesis from pineapple peel extracts. The photographs were...
Figure 2: Diffraction patterns of the reaction products Ag/AgCl-Troom, Ag/AgCl-T60, Ag/AgCl-T80, and Ag/AgCl-T...
Figure 3: EDX analysis and quantification of Ag/AgCl products at different synthesis temperatures.
Figure 4: UV–visible spectroscopy of Ag/AgCl nanoparticle biosynthesis. The maximum absorption peaks are deno...
Figure 5: FTIR spectra of Ag/AgCl nanoparticles. The functional groups of the AgNO3 salt are represented by t...
Figure 6: TEM micrographs of nanoparticles obtained at different temperatures. (a) Ag/AgCl-Troom, (b) Ag/AgCl...
Figure 7: (a) TGA data and (b) weight loss derivatives of Ag/AgCl-Troom, Ag/AgCl-T60, Ag/AgCl-T80, and Ag/AgC...
Figure 8: Cell viability assay of MCF-7 cells with Ag/AgCl nanoparticles obtained at room temperature, 60, 80...
Figure 9: Microscopic observation of control MCF-7 cells and MCF-7 cells with Ag/AgCl nanoparticles after 24 ...
Figure 10: Cell viability tests on mononuclear cells (monocytes) with Ag/AgCl nanoparticles obtained at 60 and...
Figure 11: Cell viability assays on MCF-7 cells with pineapple peel extracts obtained at room temperature, 60,...
Figure 1: Examples of combinatorial therapy for (left) EGFR-dependent and (right) EGFR-independent TKI resist...
Figure 2: (A) Gefitinib-loaded gelatin-A NPs functionalized with a cetuximab-siRNA conjugate (Ab-SiRNA-GelGEF...
Figure 3: Nanotools for reversal of EGFR TKI resistance by RNAi. Favorable cell internalization was mediated ...